Isotretinoin

Introduction Overview

Generic Name

isotretinoin

Brand Name

Absorica, Absorica LD, Accutane, Amnesteem, Claravis, ISOtretinoin (Eqv-Absorica), Myorisan, Sotret, Zenatane, ISOtretinoin (Eqv-Accutane), ISOtretinoin (Eqv-Myorisan)

Dosage Form

oral capsule (8 mg micronized; 10 mg; 16 mg micronized; 20 mg; 24 mg micronized; 25 mg; 30 mg; 32 mg micronized; 35 mg; 40 mg)

Drug Class

Miscellaneous antineoplastics, Miscellaneous uncategorized agents

Pharmacokinetics

Absorption:
Isotretinoin demonstrates variable gastrointestinal absorption, which is highly dependent on the presence of dietary fat. Oral bioavailability has been reported to increase significantly when taken with a high-fat meal, sometimes by as much as twofold, compared to a fasting state. This necessitates clinical advisement to take isotretinoin with food to optimize absorption and therapeutic efficacy. Micronized formulations have been developed to enhance bioavailability and reduce food dependency. Peak plasma concentrations are usually reached within 3 to 4 hours post-dose. Extensive interpatient variability has been observed, influenced by formulation, meal composition, and individual metabolic differences.

Distribution:
Isotretinoin is extensively distributed throughout body tissues due to its high lipophilicity. It is approximately 99.9% bound to plasma proteins, primarily albumin, which influences its volume of distribution and pharmacodynamics. The drug crosses the blood-brain barrier and placenta, which underscores its teratogenic risk. It is also detectible in sebum, contributing to its clinical action in acne treatment. Tissue concentrations are sustained due to its lipophilic nature. The distribution phase is critical as isotretinoin affects multiple organ systems and skin structures where it exerts its effects.

Metabolism:
Isotretinoin undergoes extensive hepatic metabolism primarily by cytochrome P450 enzymes, including CYP2C8 and CYP3A4 isoforms. It is isomerized reversibly to tretinoin (all-trans-retinoic acid), which is also pharmacologically active. Subsequent metabolism leads to hydroxylated metabolites such as 4-oxo-isotretinoin, which retain some biological activity. The metabolism is subject to interindividual variability, and enzyme inhibition or induction by concomitant drugs may alter isotretinoin plasma levels, necessitating clinical monitoring.

Elimination:
The elimination of isotretinoin and its metabolites occurs mainly via biliary excretion into feces, with only a minor fraction excreted in the urine. The terminal half-life of isotretinoin is approximately 10 to 20 hours, whereas its metabolites may have longer half-lives contributing to sustained effects and toxicity potential. Due to enterohepatic recycling, plasma disappearance may be prolonged. Renal impairment has minimal impact on isotretinoin elimination; however, hepatic impairment may necessitate dosage adjustment. The prolonged elimination has clinical implications for side effect persistence and teratogenic risk even after cessation of therapy.

Dosage Forms

Available Dosage Forms:
- Oral capsule: 8 mg (micronized)
- Oral capsule: 10 mg
- Oral capsule: 16 mg (micronized)
- Oral capsule: 20 mg
- Oral capsule: 24 mg (micronized)
- Oral capsule: 25 mg
- Oral capsule: 30 mg
- Oral capsule: 32 mg (micronized)
- Oral capsule: 35 mg
- Oral capsule: 40 mg

Dosages for Adults and Adolescents:
- Maintenance dose for severe nodular acne: 0.25 to 0.5 mg/kg orally twice daily
- Maximum dosage: Up to 2 mg/kg/day based on severity
- Duration of therapy: Typically up to 20 weeks depending on clinical response
- Severe or extensive acne with scarring or trunk involvement may require the higher end of dosing range
- Dosing frequency: Twice daily dosing is standard; once-daily dosing is not established as safe or efficacious

Specific Patient Populations:
- Pediatric patients aged 12 years and older: same dosing as adults with weight-based adjustments
- Not approved for children under 12 years
- Patients with hepatic impairment may require careful monitoring due to metabolism and elimination pathways
- Female patients of childbearing potential must participate in the iPLEDGE program and use dual contraception to prevent pregnancy during and for 1 month after therapy
- Formulations differ in bioavailability; micronized capsules offer improved absorption with less food dependence
- Monitoring and dose adjustments may be required in patients with pre-existing psychiatric conditions or hyperlipidemia

Clinical Guidelines:
- Capsules should be swallowed whole with a full glass of water
- Some formulations require intake with food to optimize absorption, except certain micronized forms like Absorica which may be taken without regard to meals
- Strict adherence to dosing regimen and duration recommended to reduce relapse rates and adverse effects
- Prescriptions are limited to 30-day supplies per iPLEDGE requirements with mandatory monitoring and authorization

Mechanism Of Action

Isotretinoin is a synthetic derivative of vitamin A (retinoid) that exerts its therapeutic effects primarily through modulation of gene expression and cellular differentiation in sebaceous glands and skin cells. At the molecular level, isotretinoin binds to specific nuclear receptors known as retinoic acid receptors (RARs), including RAR-alpha, RAR-beta, and RAR-gamma, as well as retinoid X receptors (RXRs). Upon binding, these receptors form heterodimers that regulate transcription of genes involved in cell proliferation, differentiation, and apoptosis, altering keratinocyte proliferation and reducing hyperkeratinization.

The drug profoundly decreases sebaceous gland size and suppresses sebum production, a key factor in acne pathogenesis. By reducing sebaceous gland activity, isotretinoin decreases the follicular colonization by Propionibacterium acnes and limits the substrate available for bacterial growth. Additionally, isotretinoin inhibits inflammation by modulating inflammatory cytokine expression and reducing neutrophil chemotaxis.

Isotretinoin also promotes normalization of follicular epithelial desquamation, reducing comedone formation. It accelerates apoptosis of sebocytes and keratinocytes, leading to decreased follicular plugging and prevention of new acne lesions. The drug’s ability to induce terminal differentiation contributes to restoration of normal skin architecture.

Comparatively, isotretinoin differs from other retinoids like tretinoin, primarily in its systemic oral delivery, allowing deeper and more sustained effects. Clinical studies confirm isotretinoin’s superior efficacy in severe, nodular, refractory acne compared to topical agents and antibiotics. Its multifactorial mechanism, involving sebum suppression, anti-inflammatory action, and normalization of keratinization, underpins its unique therapeutic profile. Research continues to elucidate additional intracellular pathways influenced by isotretinoin, including modulation of matrix metalloproteinases and oxidative stress pathways.

Pharmacological Actions

Potent reduction of sebaceous gland size and sebum production
Modulation of gene expression via retinoic acid receptors affecting cell differentiation and proliferation
Normalization of follicular epithelial desquamation, preventing comedone formation
Anti-inflammatory effects through cytokine modulation and neutrophil activity reduction
Induction of apoptosis in sebocytes and keratinocytes, decreasing follicular obstruction
Inhibition of Propionibacterium acnes colonization indirectly through sebum suppression
Systemic retinoid activity impacting skin cellular turnover and repair mechanisms
Reduction of hyperkeratinization leading to decreased acne lesions
Micronized formulations enhance bioavailability and absorption
Oral systemic retinoid effect differentiates it from topical retinoids
Modulation of matrix metalloproteinase activity influencing skin remodeling
Potential modulation of oxidative stress pathways in skin tissue
Exhibits teratogenic effects due to action on embryonic differentiation

Therapeutic Or Clinical Uses

Treatment of severe recalcitrant nodular acne resistant to conventional therapy, including systemic antibiotics
Management of cystic and nodular acne with substantial inflammatory component
Induction of prolonged remission in severe acne cases to prevent scarring
Off-label use for disorders responsive to retinoid therapy, though primarily approved for acne
Used when other topical and systemic acne treatments have failed or are contraindicated
Reduction of sebaceous gland activity in hyperseborrhea-associated dermatoses
Potential adjunct in certain granulomatous and keratinization disorders given retinoid effects
Therapeutic option under strict monitoring programs (iPLEDGE) due to teratogenicity risk
Considered the most effective systemic treatment for severe, nodular acne
Improvement of acne-related psychosocial morbidity through effective lesion reduction
Reduction in acne lesion counts by over 70% after 20 weeks of therapy in clinical studies
Prevention of acne relapse when used as a single course of therapy
Clinical improvement typically begins within 4 weeks but full effects may take months
May be used in adolescents aged 12 years and older, with appropriate monitoring
Essential in treatment regimens for patients with extensive scarring or trunk involvement

Side Or Adverse Effects

Dryness of skin, lips (cheilitis), eyes, and nasal mucosa often causing nosebleeds
Visual disturbances including blurred vision and impaired night vision
Headache, sometimes severe, potentially indicating increased intracranial pressure
Muscle and joint pain, including bone pain and back pain
Photosensitivity resulting in increased susceptibility to sunburn
Skin reactions such as rash, peeling, and irritation
Cold-like symptoms including nasal congestion, sneezing, and sore throat
Psychiatric effects including depression, mood changes, and hallucinations
Severe adverse events like pancreatitis and liver dysfunction with elevated liver enzymes
Teratogenicity leading to severe birth defects or fetal death in exposed pregnancies
Increased serum lipid levels including hypertriglyceridemia and cholesterol abnormalities
Potential for increased intracranial pressure manifesting as headaches, visual changes
Gastrointestinal symptoms such as nausea, abdominal pain, and severe stomach or chest pain
Rare reports of inflammatory bowel disease exacerbation or onset
Possible hair thinning or hair loss, typically reversible upon discontinuation

Precautions

Strict avoidance of pregnancy during therapy and for one month after cessation; mandatory contraceptive measures
Regular laboratory monitoring including liver function tests and lipid panels throughout treatment
Screening for pre-existing psychiatric disorders due to the risk of depression and mood changes
Cautious use in patients with prior history of liver disease or hyperlipidemia
Avoid use in breastfeeding due to potential excretion in breast milk and risk to infant
Not recommended for use in children under 12 years due to safety data limitations
Avoid concomitant use of vitamin A supplements to prevent additive toxicity
Avoid cosmetic procedures such as waxing, dermabrasion, or laser treatments during and for six months post-therapy to reduce scarring risk
Patient education on avoiding excessive sun exposure and use of sunscreens to prevent photosensitivity
Counsel patients on the importance of adhering to prescribed dosing and not sharing medication
Assessment of baseline bone density recommended in patients with osteoporosis risk factors
Monitoring for signs of hepatitis, pancreatitis, or increased intracranial pressure is essential
Regular pregnancy testing is mandated by iPLEDGE at specified intervals
Counsel on potential drug interactions that may affect metabolism or efficacy
Inform patients about the possibility of acne flare at treatment initiation

Warnings

Isotretinoin is highly teratogenic, causing severe fetal malformations and miscarriage even with a single dose
Use is contraindicated during pregnancy; negative pregnancy tests and dual contraception required before and during therapy
Risk of serious psychiatric adverse effects including depression, suicidal ideation, and psychosis
Potential for hepatotoxicity with elevated liver enzymes necessitates routine monitoring
Hypertriglyceridemia induced by isotretinoin may increase risk of pancreatitis
Possible increase in intracranial pressure which can cause headaches, vision changes, and neurologic symptoms
Patients must not donate blood during therapy and for at least 30 days after due to teratogenic risk to recipients
Photosensitivity can increase risk of severe sunburn; protective measures mandatory
Severe allergic reactions and skin reactions including Stevens-Johnson syndrome may occur rarely
Abrupt discontinuation without medical advice is discouraged to avoid relapse or prolonged side effects
Concomitant use with tetracyclines linked to increased risk of intracranial hypertension
Use caution in patients with a history of inflammatory bowel disease or other gastrointestinal disorders
Warning against use with vitamin A supplements to prevent additive toxicity
Potential for permanent vision impairment if ocular toxicity is not promptly recognized
Patients must be enrolled in and comply with the FDA-mandated iPLEDGE risk management program

Contraindication

Pregnancy due to high teratogenicity risk
Hypersensitivity or allergy to isotretinoin or any component of the formulation
Use in women who are unable to adhere to reliable contraception methods
Patients currently breastfeeding
Concurrent use with vitamin A supplements
Known severe hepatic impairment or active liver disease
Patients with a history of hypersensitivity to retinoids
Patients taking tetracycline antibiotics concurrently due to increased risk of pseudotumor cerebri
Severe pre-existing psychiatric disorders that are unstable or untreated
Patients with elevated serum triglycerides > 500 mg/dL uncontrolled by other measures
Individuals under 12 years of age due to lack of established safety and efficacy
Known inflammatory bowel disease flares or active ulcerative colitis
Patients who are unwilling or unable to adhere to monitoring requirements of the iPLEDGE program
History of pancreatitis associated with hypertriglyceridemia
Concurrent use of systemic retinoids or other agents with overlapping toxicities

Drug Interactions

Concomitant use with tetracycline antibiotics (e.g., doxycycline, minocycline) increases risk of intracranial hypertension
St. John's wort may reduce efficacy of hormonal contraceptives used concurrently, increasing risk of pregnancy
Progestin-only birth control pills (mini-pills) may have reduced efficacy when taken with isotretinoin
CYP3A4 inducers or inhibitors may alter metabolism and plasma concentrations of isotretinoin
Concomitant vitamin A supplements can cause additive toxicity leading to hypervitaminosis A
Steroid medications may increase the risk of side effects like bone demineralization when used together
Phenytoin may interact by altering hepatic metabolism of isotretinoin
Drugs affecting lipid metabolism may exacerbate isotretinoin-induced hyperlipidemia
CYP enzyme modulators may unpredictably affect isotretinoin pharmacokinetics
Drugs causing photosensitivity may increase risk of skin reactions when combined
Concurrent use with other retinoids increases cumulative toxicity risk
Immunosuppressants may have additive immunomodulatory effects
Concomitant use of oral contraceptives is critical to prevent pregnancy, but some interactions may reduce contraceptive efficacy
Alcohol may exacerbate hepatotoxic effects during isotretinoin therapy
Limited data exists on interactions with herbal products, necessitating caution

Preparations Of The Drug

Isotretinoin oral capsules in multiple strengths: 8 mg (micronized), 10 mg, 16 mg (micronized), 20 mg, 24 mg (micronized), 25 mg, 30 mg, 32 mg (micronized), 35 mg, 40 mg
Micronized formulations (e.g., Absorica) designed to enhance bioavailability and reduce food dependency
Formulations distributed exclusively through FDA-mandated iPLEDGE program to mitigate teratogenic risk
Each prescription limited to 30-day supply with no automatic refills; new prescription and iPLEDGE authorization required for continuation
Capsules intended to be swallowed whole with water, not to be crushed or chewed
Storage at room temperature protected from moisture, heat, and light to maintain stability
Packaging includes patient medication guide emphasizing pregnancy prevention and safety monitoring
Certain generic and brand-name preparations differ in bioavailability and dosing instructions
Patient support programs available to ensure compliance with safety protocols
Medication guides provided with each dispensation detailing side effects, precautions, and contraception requirements
Some formulations require administration with food to optimize absorption; others (micronized) may be taken without regard to meals
Compliance with iPLEDGE registration and monitoring is mandatory for all dispensations
Labeling includes warnings about blood donation prohibition during and 30 days post-therapy
Preparations are not interchangeable without clinician oversight due to variable pharmacokinetics
Dispensing pharmacies must be certified under iPLEDGE program